phrykt

Aytu Biopharma, Inc (AYTU): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of AYTU were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling AYTU Biopharma

From the latest filings

Overall: more buying than selling. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AYTU

36 funds and institutions reported AYTU shares worth $10.6M at the end of Q2 2026, about 46% of the company. The largest holder is Nantahala Capital Management, LLC with 20.3%.

Funds and institutions (13F) 46%Everyone else 54%

10 largest owners, by share of the company

Nantahala Capital Management, LLC20.3%
Stonepine Capital Management, LLC8.5%
AWM Investment Company, Inc.5.8%
Vanguard Capital Management LLC2.4%
Crown Advisors Management, Inc.1.9%
Diadema Partners LP1.4%
Two Sigma Investments, LP1.0%
Renaissance Technologies LLC1.0%
Geode Capital Management, LLC0.9%
Citadel Advisors LLC0.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nantahala Capital Management, LLC2.17M20.25%$4.7M+100%
Stonepine Capital Management, LLC912,9218.51%$2M+15%
AWM Investment Company, Inc.619,5745.77%$1.3MNo change
Vanguard Capital Management LLC261,1462.43%$561KNo change
Crown Advisors Management, Inc.200,0001.86%$430K+38%
Diadema Partners LP148,5461.38%$319K-58%
Two Sigma Investments, LP105,3260.98%$226K-14%
Renaissance Technologies LLC104,8230.98%$225K+12%
Geode Capital Management, LLC93,6470.87%$201K+1%
Citadel Advisors LLC49,4140.46%$106K+34%
Vanguard Fiduciary Trust Co47,0480.44%$101KNo change
Dimensional Fund Advisors LP45,3260.42%$97.5K+4%
Persistent Asset Partners Ltd37,9840.35%$81.7K-59%
Northern Trust Corp27,9250.26%$60K+46%
Bellevue Asset Management, LLC25,0130.23%$53.8KNo change
BlackRock, Inc.22,7930.21%$49KNo change
XTX Topco Ltd21,4160.20%$46K-1%
Acadian Asset Management LLC10,2370.10%$22KNo change
Daytona Street Capital LLC10,0000.09%$22.4KNo change
UBS Group AG2,3770.02%$5.1K+43%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No AYTU insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AYTU short interest

Low short interest. 2.8% of AYTU shares are sold short: about 1 share in 36. Over the last 12 reports the number of shares short went down 34%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 301,698 AYTU shares were sold short, 2.8% of the shares outstanding, down 8.3% from the report before. At the average daily volume of 25,896 shares, buying them all back would take about 11.7 trading days (days to cover).

Shares short, % of all shares

2.78%May 15Oct 304.49%

Days to cover

11.7May 15Oct 3017.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026301,6982.78%-8%25,89611.7
Oct 15, 2026328,8723.03%-5%23,55914.0
Sep 30, 2026345,2293.18%+11%72,7784.7
Sep 15, 2026311,6072.87%-7%24,19312.9
Aug 31, 2026334,3993.12%+4%27,08012.3
Aug 14, 2026321,5353.00%-1%32,9129.8
Jul 31, 2026326,2273.04%-6%26,10912.5
Jul 15, 2026347,0113.23%-0%21,98415.8
Jun 30, 2026348,4973.25%-2%29,14812.0
Jun 15, 2026354,3603.30%-13%29,11612.2
May 29, 2026407,9823.80%-11%46,8258.7
May 15, 2026457,7914.27%-9%64,1147.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

AYTU Biopharma company events

AYTU Biopharma filed 7 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Sep 22, 2026.

  1. Sep 22, 2026ResultsReleased financial results. Filing
  2. Jun 25, 2026AgreementEnded an important agreement. Filing
  3. May 13, 2026ResultsReleased financial results. Filing
  4. Apr 2, 2026AgreementEntry into a Definitive Material Agreement . As previously disclosed, Aytu BioPharma, Inc. completed public equity offerings in June 2023 and June 2025 whereby the Company issued certain warrants and prefunded warrants to certain institutional investors. Filing
  5. Feb 3, 2026ResultsReleased financial results. Filing
  6. Jan 20, 2026AnnouncementShared information with investors. Filing
  7. Dec 10, 2025VoteReported shareholder vote results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

AYTU Biopharma financials

Famous investors that hold AYTU

2 of the 50 well-known investors we track reported holding AYTU in their latest 13F filing. The largest position is Jim Simons's, worth $260K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026121,623$260K0.0%+16%
Ken Griffin · Citadel AdvisorsQ3 202612,678$27.1K0.0%-74%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Aytu Biopharma, Inc (AYTU) stock

Who owns the most AYTU stock?

The largest reported owner of Aytu Biopharma, Inc (AYTU) is Nantahala Capital Management, LLC, with 20.3% of the company. In total, 36 funds and institutions reported holding AYTU at the end of Q2 2026, together about 46% of the shares. See the largest owners.

Are AYTU insiders buying or selling?

No AYTU insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in AYTU?

As of Oct 30, 2026, 301,698 AYTU shares were sold short, 2.8% of the shares outstanding, down 8.3% from the report before. At the average daily volume of 25,896 shares, buying them all back would take about 11.7 trading days (days to cover). See the history.

Which famous investors hold AYTU?

2 of the 50 well-known investors we track reported AYTU in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $260K. See all holders.

Executive pay

AYTU Biopharma's chief executive was paid a total of $845K for the year ended Jun 30, 2026, down 4% from $884K the year before. In the last 12 months, AYTU Biopharma's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$845KYear ended Jun 30, 2026. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$855KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$553KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.